Cargando…
Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure–property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799160/ https://www.ncbi.nlm.nih.gov/pubmed/33458565 http://dx.doi.org/10.1007/s42452-020-04051-9 |
_version_ | 1783635105587134464 |
---|---|
author | Lipin, Raju Dhanabalan, Anantha Krishnan Gunasekaran, Krishnasamy Solomon, Rajadurai Vijay |
author_facet | Lipin, Raju Dhanabalan, Anantha Krishnan Gunasekaran, Krishnasamy Solomon, Rajadurai Vijay |
author_sort | Lipin, Raju |
collection | PubMed |
description | Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure–property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluate its bimolecular interactions with Nipah virus. The geometrical features of all the molecules have been addressed from Density Functional Theory calculations. Chemical reactivity descriptor analysis was carried out to understand various reactivity parameters. The drug-likeness properties were estimated by a detailed ADMET study. The binding ability and the mode of binding of these derivatives into the Nipah virus are obtained from molecular docking studies. Our calculations show greater binding ability for the designed inhibitors compared to that of the experimentally reported molecule. Overall, the present work proves to offers new insights and guidelines for synthetic chemists to develop new drugs using piperazine substituted Favipiravir in the treatment of Nipah virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42452-020-04051-9. |
format | Online Article Text |
id | pubmed-7799160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-77991602021-01-12 Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? Lipin, Raju Dhanabalan, Anantha Krishnan Gunasekaran, Krishnasamy Solomon, Rajadurai Vijay SN Appl Sci Research Article Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure–property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluate its bimolecular interactions with Nipah virus. The geometrical features of all the molecules have been addressed from Density Functional Theory calculations. Chemical reactivity descriptor analysis was carried out to understand various reactivity parameters. The drug-likeness properties were estimated by a detailed ADMET study. The binding ability and the mode of binding of these derivatives into the Nipah virus are obtained from molecular docking studies. Our calculations show greater binding ability for the designed inhibitors compared to that of the experimentally reported molecule. Overall, the present work proves to offers new insights and guidelines for synthetic chemists to develop new drugs using piperazine substituted Favipiravir in the treatment of Nipah virus. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42452-020-04051-9. Springer International Publishing 2021-01-11 2021 /pmc/articles/PMC7799160/ /pubmed/33458565 http://dx.doi.org/10.1007/s42452-020-04051-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Lipin, Raju Dhanabalan, Anantha Krishnan Gunasekaran, Krishnasamy Solomon, Rajadurai Vijay Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? |
title | Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? |
title_full | Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? |
title_fullStr | Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? |
title_full_unstemmed | Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? |
title_short | Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel? |
title_sort | piperazine-substituted derivatives of favipiravir for nipah virus inhibition: what do in silico studies unravel? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799160/ https://www.ncbi.nlm.nih.gov/pubmed/33458565 http://dx.doi.org/10.1007/s42452-020-04051-9 |
work_keys_str_mv | AT lipinraju piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel AT dhanabalanananthakrishnan piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel AT gunasekarankrishnasamy piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel AT solomonrajaduraivijay piperazinesubstitutedderivativesoffavipiravirfornipahvirusinhibitionwhatdoinsilicostudiesunravel |